A detailed history of Bellevue Group Ag transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Bellevue Group Ag holds 58,729 shares of BGNE stock, worth $11.1 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
58,729
Previous 25,629 129.15%
Holding current value
$11.1 Million
Previous $3.66 Million 260.64%
% of portfolio
0.22%
Previous 0.06%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$143.93 - $224.51 $4.76 Million - $7.43 Million
33,100 Added 129.15%
58,729 $13.2 Million
Q2 2024

Aug 14, 2024

BUY
$129.52 - $174.32 $90,664 - $122,024
700 Added 2.81%
25,629 $3.66 Million
Q1 2024

May 15, 2024

SELL
$141.8 - $181.47 $520,547 - $666,176
-3,671 Reduced 12.84%
24,929 $3.9 Million
Q4 2023

Feb 14, 2024

SELL
$158.67 - $201.58 $3.9 Million - $4.96 Million
-24,600 Reduced 46.24%
28,600 $5.16 Million
Q3 2023

Nov 14, 2023

BUY
$179.87 - $225.13 $7.73 Million - $9.68 Million
43,000 Added 421.57%
53,200 $9.57 Million
Q2 2023

Aug 14, 2023

SELL
$178.3 - $266.78 $8.56 Million - $12.8 Million
-48,035 Reduced 82.48%
10,200 $1.82 Million
Q1 2023

May 15, 2023

BUY
$215.53 - $274.5 $5.12 Million - $6.52 Million
23,735 Added 68.8%
58,235 $12.6 Million
Q4 2022

Feb 14, 2023

BUY
$125.51 - $229.3 $3.45 Million - $6.31 Million
27,500 Added 392.86%
34,500 $7.59 Million
Q3 2022

Nov 14, 2022

BUY
$131.8 - $202.24 $922,600 - $1.42 Million
7,000 New
7,000 $940,000
Q1 2022

May 13, 2022

SELL
$146.52 - $269.56 $3.37 Million - $6.2 Million
-23,000 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$249.6 - $403.14 $15.3 Million - $24.7 Million
-61,300 Reduced 72.72%
23,000 $8.35 Million
Q2 2021

Aug 12, 2021

BUY
$292.75 - $367.01 $7.2 Million - $9.03 Million
24,600 Added 41.21%
84,300 $28.9 Million
Q1 2021

May 12, 2021

SELL
$260.64 - $382.12 $12.4 Million - $18.1 Million
-47,400 Reduced 44.26%
59,700 $20.8 Million
Q4 2020

Feb 16, 2021

BUY
$221.31 - $316.61 $15 Million - $21.4 Million
67,700 Added 171.83%
107,100 $27.7 Million
Q3 2020

Nov 16, 2020

SELL
$189.18 - $286.44 $3.52 Million - $5.33 Million
-18,600 Reduced 32.07%
39,400 $11.3 Million
Q2 2020

Aug 13, 2020

SELL
$123.9 - $195.41 $61,950 - $97,705
-500 Reduced 0.85%
58,000 $10.9 Million
Q1 2020

May 14, 2020

BUY
$121.84 - $173.19 $1.42 Million - $2.02 Million
11,644 Added 24.85%
58,500 $7.2 Million
Q4 2019

Feb 14, 2020

SELL
$115.78 - $208.34 $2.92 Million - $5.26 Million
-25,244 Reduced 35.01%
46,856 $7.77 Million
Q3 2019

Nov 14, 2019

SELL
$120.61 - $148.29 $2.52 Million - $3.1 Million
-20,900 Reduced 22.47%
72,100 $8.98 Million
Q2 2019

Aug 14, 2019

SELL
$113.99 - $146.86 $1.05 Million - $1.35 Million
-9,200 Reduced 9.0%
93,000 $11.5 Million
Q1 2019

May 15, 2019

BUY
$122.82 - $151.83 $2.28 Million - $2.82 Million
18,600 Added 22.25%
102,200 $13.5 Million
Q4 2018

Feb 12, 2019

BUY
$107.01 - $175.15 $7.7 Million - $12.6 Million
71,980 Added 619.45%
83,600 $11.7 Million
Q3 2018

Nov 13, 2018

BUY
$152.62 - $189.66 $18,314 - $22,759
120 Added 1.04%
11,620 $2 Million
Q2 2018

Aug 07, 2018

SELL
$152.5 - $216.77 $4.45 Million - $6.32 Million
-29,150 Reduced 71.71%
11,500 $1.77 Million
Q1 2018

May 09, 2018

SELL
$97.41 - $177.22 $6.14 Million - $11.2 Million
-63,000 Reduced 60.78%
40,650 $6.83 Million
Q4 2017

Feb 14, 2018

BUY
$79.6 - $114.73 $8.25 Million - $11.9 Million
103,650
103,650 $10.1 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $19.6B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.